Unity Biotechnology logo

Unity BiotechnologyNASDAQ: UBX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 May 2018

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$21.40 M
-88%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector
-65%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 7 min ago
$1.27-$0.06(-4.51%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

UBX Latest News

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
globenewswire.com04 November 2024 Sentiment: -

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.

UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
zacks.com09 August 2024 Sentiment: POSITIVE

UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
globenewswire.com06 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024.

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
globenewswire.com22 July 2024 Sentiment: POSITIVE

SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies.

All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
zacks.com17 May 2024 Sentiment: POSITIVE

There is increasing optimism about UNITY Biotechnology's earnings prospects, leading to its upgrade to a Zacks Rank #2 (Buy) and potential for a rise in stock price.

Unity (UNX) Down on Disappointing Results From Wet AMD Study
Zacks Investment Research28 March 2023 Sentiment: NEGATIVE

Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.

Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
InvestorPlace27 March 2023 Sentiment: NEGATIVE

Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).

What type of business is Unity Biotechnology?

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

What sector is Unity Biotechnology in?

Unity Biotechnology is in the Healthcare sector

What industry is Unity Biotechnology in?

Unity Biotechnology is in the Biotechnology industry

What country is Unity Biotechnology from?

Unity Biotechnology is headquartered in United States

When did Unity Biotechnology go public?

Unity Biotechnology initial public offering (IPO) was on 03 May 2018

What is Unity Biotechnology website?

https://unitybiotechnology.com

Is Unity Biotechnology in the S&P 500?

No, Unity Biotechnology is not included in the S&P 500 index

Is Unity Biotechnology in the NASDAQ 100?

No, Unity Biotechnology is not included in the NASDAQ 100 index

Is Unity Biotechnology in the Dow Jones?

No, Unity Biotechnology is not included in the Dow Jones index

When was Unity Biotechnology the previous earnings report?

No data

When does Unity Biotechnology earnings report?

The next expected earnings date for Unity Biotechnology is 13 November 2024